GOLD MOUNTAIN RESEARCH

Building innovative scientific solutions for major planetary challenges of our time
Our Approach
/ Our story

Pragmatic & focused innovations - powered by deep science - at the heart of gold mountain research

Welcome to Gold Mountain Research (GMR) of Pittsburgh, PA, whose roots go back to Stanford University. GMR is a privately operated research center leveraging strengths in biophysics, computation, molecular design & transmutation, off-the-beaten-path drug discovery, and microbiology. GMR is also incubating a concept for Greenhouse Gas reduction, to be tested in the lab, then piloted in the Pittsburgh region.
Focused Innovations - the leaders “have been around the block, not the first rodeo!” After 4 decades of service in academia, in platform biotechs (with successful exits by acquisition), in government labs (NCI in Frederick), and top leader as the Chief Executive of a non-profit research lab, we have seen many innovations launch. As a result, GMR takes great effort applying a highly selective approach to the selection of appropriate technologies and programs within each strategic goal area.
/ Our STRATEGY

GMR pursues global-scale challenges of:


* GLOBAL HEALTH * PULMONARY INFECTIONS and ANTI-MICROBIAL RESISTANCE (AMR)
* JOINING THE FIGHT AGAINST CLIMATE CHANGE
our portfolio includes high IMPORTANCE target spaces
  • : innovation for greenhouse gas reduction :
  • : in life sciences, global health needs being neglected by new medicinal modalities :
phased with timing matched to collaborations
: Anti-Microbial Resistance : Achilles Heel attack capable of sterilizing drug-resistant Mycobacterium tuberculosis (TB) :
gmr programs may be computation-intensive
: chemical evolution in drug design and lead-to-IND optimization : enablement of large-scale panoramic 3D navigation across small molecule drugs for search and retrieval by AI :

/ Current Programs

Funding and collaborations are at various stages. GMR-46 team will be launched as funding and collaborators are established. Joining the fight against Climate Change: reducing greenhouse gas emissions with a pragmatic new technology. Seed funding will be powerfully catalytic to implement this invention. Inquiries from investors welcome. Strategic drug discovery collaborations: include those with a closely affiliated non-profit Platform TechBio, known as the Institute for Molecular Intelligence. This features tech platforms mintAI, and GMR-MV4AI, a set of novel physics-based computational algorithms that will transform the ability of AI driven search and retrieval for new medicines. De novo lead discovery on high-importance targets, and powerful hit and lead-to-IND optimization, and scaffold-hopping to provide vision into new alternatives that leverage clinically-experienced drug candidates, are all enabled by this nextgen AI technology. Disease areas: TB: Tuberculosis, which kills 1.4 million annually; AntiMicrobial Resistance (AMR): the growing 21st century problem for the treatment of many bacterial infections, including TB. Resistant pathogens are a serious problem in HAI (Hospital-Acquired Infections). Infection by antibiotic-resistant bacteria threatens to throw the patient back in time to the pre-modern era, with far higher morbidity and mortality. U2: a novel mode for oral small molecule therapeutics to moderate inflammatory and rheumatoid diseases (large market), empowered by biophysics expertise.
/ about us

strengths by 4 decades of innovation

Contact: akuki@goldmountainresearch.com or via: linkedin.com/in/atsuokuki
The founder, Dr. Atsuo Kuki, earned his PhD in 1985 from Stanford University, and has spent 14 years in La Jolla, CA in a private computational and parallel synthesis platform biotech, acquired by a public structure-based drug design R&D biotech, acquired by Parke-Davis, acquired by Pfizer… then served as an executive and technology leader within Pfizer La Jolla R&D Academic training was in protein biophysics & spectroscopy, picosecond lasers, theoretical quantum biophysics (early days of Cray Supercomputers), Feynman path integrals, path integral Monte Carlo (quantum stat mech; electron transfer theory) Relevant drug discovery technologies: parallel synthesis, library design, cycles of retrosynthesis and forward synthesis during lead optimization, target protein expression and crystallization, SBDD, biophysical MassSpec, chemical datasystems, JAVA (Pfizer Global Virtual Library tools) Leader of team leaders, integration of diverse biotech and pharma R&D cultures, global Pfizer R&D technology ambassador and diplomat. Effective in working across silos. Awarded the Pfizer Global R&D Achievement Award for multi-site drug discovery technology leadership Front-line experience with government contracting, operating as a leader in the FFRDC (Leidos) for the National Cancer Institute in Frederick, MD President of Trudeau Institute, Saranac Lake NY. Infectious diseases research laboratory with an honored and eminent place in the history of TB (Edward Livingston Trudeau, 1884)